Home » Stocks » ARVN

Arvinas, Inc. (ARVN)

Stock Price: $90.79 USD 0.19 (0.21%)
Updated Jan 19, 2021 3:46 PM EST - Market open
Market Cap 4.29B
Revenue (ttm) 24.48M
Net Income (ttm) -98.83M
Shares Out 39.06M
EPS (ttm) -2.59
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 19
Last Price $90.79
Previous Close $90.60
Change ($) 0.19
Change (%) 0.21%
Day's Open 92.61
Day's Range 90.07 - 92.77
Day's Volume 294,647
52-Week Range 20.19 - 92.77

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
Seeking Alpha - 2 weeks ago

Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer.

GlobeNewsWire - 3 weeks ago

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation usi...

Benzinga - 3 weeks ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. So insider bu...

Other stocks mentioned: FL, GME, NTAP, BCAB, COUP, EOSE, GWRE, JKHY, MBIO, ODT, UPST, VST
GlobeNewsWire - 1 month ago

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation usi...

Zacks Investment Research - 1 month ago

Arvinas (ARVN) announces promising interim data on its two clinical stage pipeline candidates, ARV-471 and ARV-110, for treating breast cancer and prostate cancer, respectively.

GlobeNewsWire - 1 month ago

NEW HAVEN, Conn., Dec. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation usi...

Benzinga - 1 month ago

Even as the broader market trades higher in reaction to the availability of the first coronavirus vaccine under emergency use authorization, a slew of biopharma stocks are moving on company-sp...

Other stocks mentioned: ANPC, ARPO, SYBX, VERU
InvestorPlace - 1 month ago

Arvinas (ARVN) news for Monday includes positive interim results from clinical trials sending ARVN stock soaring to new highs. The post Arvinas News Alert: Why ARVN Stock Is Skyrocketing Today...

GlobeNewsWire - 1 month ago

– ARV-471 demonstrates evidence of anti-tumor activity, and potential for best-in-class safety, and estrogen receptor (ER) degradation profile and robust efficacy signals in a heavily pretreat...

GlobeNewsWire - 1 month ago

– Event to be webcast live on Monday, December 14, 2020 at 8:00 a.m. ET –

GlobeNewsWire - 1 month ago

NEW HAVEN, Conn., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to...

GlobeNewsWire - 2 months ago

– First patient dosed in Phase 2 dose expansion cohort of ARV-110 trial –

GlobeNewsWire - 3 months ago

NEW HAVEN, Conn., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to...

GlobeNewsWire - 3 months ago

NEW HAVEN, Conn., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, to...

GlobeNewsWire - 4 months ago

NEW HAVEN, Conn., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 07, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, ...

Zacks Investment Research - 5 months ago

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -12.07% and 0.40%, respectively, for the quarter ended June 2020.

GlobeNewsWire - 5 months ago

NEW HAVEN, Conn., Aug. 04, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biopharmaceutical company creating a new class of drugs based on targeted protein degradati...

Zacks Investment Research - 5 months ago

Arvinas, Inc. (ARVN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

GlobeNewsWire - 6 months ago

NEW HAVEN, Conn., June 29, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, ...

GlobeNewsWire - 7 months ago

NEW HAVEN, Conn., June 17, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, ...

GlobeNewsWire - 7 months ago

NEW HAVEN, Conn., June 11, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, ...

Zacks Investment Research - 7 months ago

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

GlobeNewsWire - 7 months ago

- Clear efficacy signal with two ongoing confirmed PSA responses, including one associated with a confirmed RECIST response -

Benzinga - 8 months ago

The American Society of Clinical Oncology annual conference brings together oncology professionals, patient advocates, industry representatives, and major media outlets from across the globe.

Other stocks mentioned: ALLO, AMGN, CTMX, MGNX
The Motley Fool - 8 months ago

Investors were hoping for better initial data from an early-stage trial of its prostate cancer therapy.

GlobeNewsWire - 8 months ago

- Describes the first evidence of clinical benefit for PROTAC® protein degraders, a novel therapeutic modality -

Zacks Investment Research - 8 months ago

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 8 months ago

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Benzinga - 8 months ago

Shares of Arvinas (NASDAQ:ARVN) rose 1.5% after the company reported Q1 results.

Zacks Investment Research - 8 months ago

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of 5.08% and 20.46%, respectively, for the quarter ended March 2020.

GlobeNewsWire - 9 months ago

NEW HAVEN, Conn., April 13, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...

GlobeNewsWire - 9 months ago

NEW HAVEN, Conn., March 31, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation,...

Zacks Investment Research - 9 months ago

Is (ARVN) Outperforming Other Medical Stocks This Year?

Zacks Investment Research - 10 months ago

Arvinas (ARVN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Zacks Investment Research - 10 months ago

Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -5.66% and 2.69%, respectively, for the quarter ended December 2019.

Zacks Investment Research - 11 months ago

Arvinas, Inc. (ARVN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects.

Zacks Investment Research - 11 months ago

As of late, it has definitely been a great time to be an investor in Arvinas.

GlobeNewsWire - 1 year ago

Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience Dr. Smaldone Alsup Brings Additional Product Commercialization and Global Regulatory Experience

Benzinga - 1 year ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it.

Other stocks mentioned: DBX, TRN
GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

Zacks Investment Research - 1 year ago

Arvinas, Inc. (ARVN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

The Motley Fool - 1 year ago

Can these recent highfliers keep climbing?

Other stocks mentioned: BIIB
GlobeNewsWire - 1 year ago

-Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of certain cancers

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc., (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced...

GlobeNewsWire - 1 year ago

NEW HAVEN, Conn., Oct. 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, announced that ...

Benzinga - 1 year ago

Arvinas Inc's (NASDAQ: ARVN) two lead assets have a “high likelihood of success” in their respective indications, according to Wedbush.

GlobeNewsWire - 1 year ago

Trial is evaluating the safety and tolerability of ARV-471 in patients with locally advanced or metastatic ER positive / HER2 negative breast cancer Trial is evaluating the safety and tolerabi...

Seeking Alpha - 1 year ago

Shares are trading at a 10% discount to IPO price point, and current weakness is attributable to lockup expiration.

About ARVN

Arvinas, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company's lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast ca... [Read more...]

Industry
Biotechnology
IPO Date
Sep 27, 2018
CEO
Dr. John G. Houston Ph.D.
Employees
133
Stock Exchange
NASDAQ
Ticker Symbol
ARVN
Full Company Profile

Financial Performance

In 2019, Arvinas's revenue was $42.98 million, an increase of 200.03% compared to the previous year's $14.32 million. Losses were -$70.29 million, 69.5% more than in 2018.

Financial Statements

Analyst Forecasts

According to 10 analysts, the average rating for Arvinas stock is "Strong Buy." The 12-month stock price forecast is 94.40, which is an increase of 3.98% from the latest price.

Price Target
$94.40
(3.98% upside)
Analyst Consensus: Strong Buy